Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Goodwill & Intangibles (2020 - 2025)

Northwest Biotherapeutics' Goodwill & Intangibles history spans 6 years, with the latest figure at $5.9 million for Q4 2025.

  • Quarterly results put Goodwill & Intangibles at $5.9 million for Q4 2025, up 207.19% from a year ago — trailing twelve months through Dec 2025 was $5.9 million (up 207.19% YoY), and the annual figure for FY2025 was $5.9 million, up 207.19%.
  • Goodwill & Intangibles for Q4 2025 was $5.9 million at Northwest Biotherapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $5.9 million in Q4 2025 to a low of $1.9 million in Q1 2021.
  • The 5-year median for Goodwill & Intangibles is $1.9 million (2021), against an average of $2.1 million.
  • The sharpest move saw Goodwill & Intangibles fell 1.44% in 2021, then soared 207.19% in 2025.
  • Year by year, Goodwill & Intangibles stood at $1.9 million in 2021, then changed by 0.0% to $1.9 million in 2022, then changed by 0.0% to $1.9 million in 2023, then changed by 0.0% to $1.9 million in 2024, then soared by 207.19% to $5.9 million in 2025.
  • According to Business Quant data, Goodwill & Intangibles over the past three periods came in at $5.9 million, $1.9 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.